Predicting analysis times in randomized clinical trials

被引:30
作者
Bagiella, E [1 ]
Heitjan, DF [1 ]
机构
[1] Columbia Univ, Mailman Sch Publ Hlth, Div Biostat, New York, NY 10032 USA
关键词
D O I
10.1002/sim.843
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Randomized clinical trial designs commonly include one or more planned interim analyses. At these times an external monitoring committee reviews the accumulated data and determines whether it is scientifically and ethically appropriate for the study to continue. With failure-time endpoints, it is common to schedule analyses at the times of occurrence of specified landmark events, such as the 50th event, the 100th event, and so on. Because interim analyses can impose considerable logistical burdens, it is worthwhile predicting their timing as accurately as possible. We describe two model-based methods for making such predictions during the course of a trial. First, we obtain a point prediction by extrapolating the cumulative mortality into the future and selecting the date when the expected number of deaths is equal to the landmark number. Second, are use a Bayesian simulation scheme to generate a predictive distribution of milestone times; prediction intervals are quantiles of this distribution. We illustrate our method with an analysis of data from a trial of immunotherapy in the treatment of chronic granulomatous disease. Copyright (C) 2001 John Wiley & Sons, Ltd.
引用
收藏
页码:2055 / 2063
页数:9
相关论文
共 12 条
[1]   A CONTROLLED TRIAL OF INTERFERON-GAMMA TO PREVENT INFECTION IN CHRONIC GRANULOMATOUS-DISEASE [J].
EZEKOWITZ, RAB .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (08) :509-516
[2]  
Fleming T. R., 1991, COUNTING PROCESSES S
[3]  
Fleming TR., 1992, STAT SCI, V7, P428
[4]   AN AID TO DATA MONITORING IN LONG-TERM CLINICAL-TRIALS [J].
HALPERIN, M ;
LAN, KKG ;
WARE, JH ;
JOHNSON, NJ ;
DEMETS, DL .
CONTROLLED CLINICAL TRIALS, 1982, 3 (04) :311-323
[5]  
Kalbfleisch J.D., 1980, The statistical analysis of failure time data
[6]   EVALUATION OF SAMPLE-SIZE AND POWER FOR ANALYSES OF SURVIVAL WITH ALLOWANCE FOR NONUNIFORM PATIENT ENTRY, LOSSES TO FOLLOW-UP, NONCOMPLIANCE, AND STRATIFICATION [J].
LACHIN, JM ;
FOULKES, MA .
BIOMETRICS, 1986, 42 (03) :507-519
[7]   GROUP SEQUENTIAL-PROCEDURES - CALENDAR VERSUS INFORMATION TIME [J].
LAN, KKG ;
DEMETS, DL .
STATISTICS IN MEDICINE, 1989, 8 (10) :1191-1198
[8]   MULTIPLE TESTING PROCEDURE FOR CLINICAL-TRIALS [J].
OBRIEN, PC ;
FLEMING, TR .
BIOMETRICS, 1979, 35 (03) :549-556
[9]   The REMATCH trial: Rationale, design, and end points [J].
Rose, EA ;
Moskowitz, AJ ;
Packer, M ;
Sollano, JA ;
Williams, DL ;
Tierney, AR ;
Heitjan, DF ;
Meier, P ;
Ascheim, DD ;
Levitan, RG ;
Weinberg, AD ;
Stevenson, LW ;
Shapiro, PA ;
Lazar, RM ;
Watson, JT ;
Goldstein, DJ ;
Gelijns, AC .
ANNALS OF THORACIC SURGERY, 1999, 67 (03) :723-730
[10]   PLANNING THE DURATION OF A COMPARATIVE CLINICAL-TRIAL WITH LOSS TO FOLLOW-UP AND A PERIOD OF CONTINUED OBSERVATION [J].
RUBINSTEIN, LV ;
GAIL, MH ;
SANTNER, TJ .
JOURNAL OF CHRONIC DISEASES, 1981, 34 (9-10) :469-479